Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
46 Results for "
neuroinflammatory diseases
" in MedChemExpress (MCE) Product Catalog:
Products (46)
46 Results for "neuroinflammatory diseases" in MCE Product Catalog:
5
5 Cited Publications
Research Areas:
MAPK-IN-1 (Compound 2) is a MAPK signaling pathway inhibitor. MAPK-IN-1 exhibits AChE inhibitory activity with an IC50 of 23.84 μM. MAPK-IN-1 shows anti-neuroinflammatory and neuroprotective activity and can be used for Alzheimer's disease research .
1
Target:
Research Areas:
1
1 Cited Publications
Cat. No.: HY-W019670
CAS No.: 3768-18-1
1
1 Cited Publications
Research Areas:
Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
NF-κB-IN-4 (compound 17) is a potent NF-κB pathway inhibitor with blood brain barrier (BBB) permeability. NF-κB-IN-4 exhibits potential anti-neuroinflammatory activity with low toxicity. NF-κB-IN-4 can block the activation and phosphorylation of IκBα, reduce expression of NLRP3, and thus inhibit NF-κB activation. NF-κB-IN-4 can be used for neuroinflammation related diseases research .
1
1 Cited Publications
Target:
Research Areas:
MAO-B-IN-8 is a potent reversible MAO-B inhibitor and an inhibitor of microglial production of neuroinflammatory mediator. MAO-B-IN-8 can be used for neurodegenerative disease research .
Synonyms: MIN-102; Hydroxypioglitazone
Target:
Research Areas:
Neurological Disease Metabolic Disease Inflammation/Immunology
Leriglitazone (MIN-102; Hydroxypioglitazone) is an orally active and a BBB-penetrable PPARγ agonist with an EC50 of 9 μM. Leriglitazone, as a regulator of mitochondrial function, has neuroprotective, anti-inflammatory and antioxidant effects. Leriglitazone can be used in the study of neuroinflammatory and neurodegenerative diseases .
Cat. No.: HY-W009081
CAS No.: 2433-96-7
Target:
Synonyms: MIN-102 hydrochloride; Hydroxypioglitazone hydrochloride
Target:
Research Areas:
Neurological Disease Metabolic Disease Inflammation/Immunology
Leriglitazone (MIN-102; Hydroxypioglitazone) hydrochloride is an orally active and a BBB-penetrable PPARγ agonist with an EC50 of 9 μM. Leriglitazone hydrochloride, as a regulator of mitochondrial function, has neuroprotective, anti-inflammatory and antioxidant effects. Leriglitazone hydrochloride can be used in the study of neuroinflammatory and neurodegenerative diseases .
Cat. No.: HY-W753593
Cat. No.: HY-162359
CAS No.: 2573211-25-1
Target:
Research Areas:
BIO-7488 is an orally active, selective and blood-brain barrier permeable IRAK4 inhibitor, with an IC50 value of 0.5 nM. BIO-7488 inhibits the production of pro-inflammatory cytokines (IL-1β, TNFα, IL-6) and demonstrates anti-inflammatory effects in both LPS (HY-D1056) and distal hypoxic-middle cerebral artery occlusion (DH-MCAO) ischemic stroke model. BIO-7488 can be used for the study of neuroinflammatory-related diseases, particularly ischemic stroke .
Cat. No.: HY-W019670R
CAS No.: 3768-18-1
Category:
Cat. No.: HY-P5121A
Target:
Research Areas:
Cat. No.: HY-177531
CAS No.: 2796227-17-1
Target:
Research Areas:
S-Ac7-DOG is a cationic lipid with biodegradability, low immunogenicity and high nucleic acid transfection capacity, which is commonly used to construct lipid nanoparticles for nucleic acid molecule delivery. S-Ac7-DOG can bind to mRNA, microRNA and self-amplifying RNA through electrostatic interaction. Lipid nanoparticles formed by S-Ac7-DOG enter cells via an energy-dependent endocytic pathway, release nucleic acid cargos, induce antigen-specific CD8 + T cell responses, promote the generation of precursor memory T cells, and regulate neuroinflammatory pathways. S-Ac7-DOG can be used in the research of retinal diseases, neuroinflammation and cancer .
Cat. No.: HY-125251
CAS No.: 1158231-00-5
Target:
Research Areas:
D159153 is a highly selective phosphodiesterase 4 (PDE4) inhibitor. D159153 is promising for research of asthma, chronic obstructive pulmonary disease (COPD), and neuroinflammatory disorders .
Cat. No.: HY-143721
CAS No.: 2671028-06-9
Target:
Research Areas:
Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
SSAO inhibitor-2 is a selective semicarbazide-sensitive amine oxidase (SSAO/VAP-1) inhibitor with an IC50 of < 10 nM. SSAO inhibitor-2 can be used for the research of inflammation diseases, diabetes and diabetes-related diseases, mental disorders, pain-related diseases, ischemic diseases, vascular diseases, ocular diseases, fibrosis, neuroinflammatory diseases, cancer, and tissue transplant rejection .
Target:
Research Areas:
Neurological Disease Metabolic Disease Inflammation/Immunology
PPARγ agonist 14 (compound 3) is a PPARy agonist (EC50=2.4 μM) with anti-diabetic activity. PPARγ agonist 14 can improve intracellular glucose uptake, promote insulin release, and lower blood sugar. In addition, PPARγ agonist 14 also improves mitochondrial function, reduces oxidative stress, and inhibits inflammatory factors. PPARγ agonist 14 can be used in the study of neurodegenerative diseases, neuroinflammatory diseases, and other diseases .
Target:
Research Areas:
LZWL02003 is an anti-neuroinflammatory agent. LZWL02003 has protective effect on MPP +-induced neuronal damage, and reduces the expression of ROS. LZWL02003 improves cognition, memory, learning, and athletic ability in a Rotenone (HY-B1756)-induced PD rat model. LZWL02003 can be used for research of neurodegenerative disease .
Cat. No.: HY-175655
CAS No.: 3077831-11-6
Research Areas:
BChE/p38-α MAPK-IN-1 is a selective dual inhibitor of hBChE (IC50 = 772 nM) and p38α MAPK (IC50 = 191 nM). BChE/p38-α MAPK-IN-1 reduces the production of pro-inflammatory cytokines (IL-1β, IL-6, IL-8, TNF-α) in cells. BChE/p38-α MAPK-IN-1 improves Scopolamine (HY-N0296)-induced cognitive impairment, as well as alleviates LPS (HY-D1056)-induced spatial learning impairment and exerts anti-neuroinflammatory effects in mice. BChE/p38-α MAPK-IN-1 can be used for the study of Alzheimer’s disease (AD) by targeting both cholinergic deficit and neuroinflammation .
Cat. No.: HY-N1818
CAS No.: 113122-54-6
Synonyms: 3-Deoxysappanone B
Target:
Cat. No.: HY-163695
CAS No.: 1209698-02-1
Target:
Research Areas:
NLRP3-IN-41 (compd S-9) is an orally active and brain-penetrant NLRP3 inhibitor with anti-inflammatory activities, anti-neuroinflammatory effect and without obvious cytotoxicity. NLRP3-IN-41 inhibits the priming and activation stages of the NLRP3 inflammasome and can be used for inflammasome-related diseases research .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
